DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
PSN-632,408 is an investigational drug.
There have been 7 clinical trials for PSN-632,408. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. The leading clinical trial sponsors are Sanofi, University of Toronto, and University of Alberta.
There are eighty US patents protecting this investigational drug and seven hundred and eighty-one international patents.
Recent Clinical Trials for PSN-632,408
|Topical Vancomycin Over Sternal Edge in Cardiac Surgery||National Cheng-Kung University Hospital||Phase 4|
|Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study||University of Alberta||N/A|
|Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study||University of Toronto||N/A|
Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PSN-632,408||Start Trial||Compositions and methods for diagnosis and treatment of metabolic syndrome||The United States of America, as Represented by the Secretary of the Navy (Washington, DC)||Start Trial|
|PSN-632,408||Start Trial||Biguanide compositions and methods of treating metabolic disorders||ELCELYX THERAPEUTICS, INC. (San Diego, CA)||Start Trial|
|PSN-632,408||Start Trial||Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk||ELCELYX THERAPEUTICS, INC. (San Diego, CA)||Start Trial|
|PSN-632,408||Start Trial||Generation of muscle lineage cells and therapeutic uses thereof||GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA)||Start Trial|
|PSN-632,408||Start Trial||Compositions and methods for diagnosis and treatment of inflammation||The United States of America as represented by the Secretary of the Navy (Washington, DC)||Start Trial|
|PSN-632,408||Start Trial||Biguanide compositions and methods of treating metabolic disorders||Anji Pharma (US) LLC (Boxford, MA)||Start Trial|
|PSN-632,408||Start Trial||Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals||Sanofi-Aventis (Paris, FR)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PSN-632,408||European Patent Office||EP3247346||2035-01-07||Start Trial|
|PSN-632,408||World Intellectual Property Organization (WIPO)||WO2016111843||2035-01-07||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|